Author(s): Subhash Chand, Anu Sharma, Jai Prakash Prasad, Girish Sharma

Email(s): sharmagi03@gmail.com , gsharma3@amity.edu.

DOI: 10.52711/0974-360X.2022.00982   

Address: Subhash Chand1,2, Anu Sharma1, Jai Prakash Prasad1, Girish Sharma2,3*
1National Institute of Biologicals (Ministry of Health and Family Welfare, Government of India), Plot No.A-32, Sector - 62, Institutional Area, Noida, Uttar Pradesh - 201309, India.
2Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University Uttar Pradesh, Sector - 125, Noida, Uttar Pradesh - 201313, India.
3Amity Centre for Cancer Epidemiology and Cancer Research, Amity University Uttar Pradesh, Sector - 125, Noida, Uttar Pradesh - 201313, India.
*Corresponding Author

Published In:   Volume - 15,      Issue - 12,     Year - 2022


ABSTRACT:
Multi-targeted drug combinations which selectively inhibit the proliferation of cancer cells are required for effective anticancer treatment. The current anti-HER2 positive breast cancer therapy involves Trastuzumab and doxorubicin drug combination which produces toxic side effects in clinical settings including high cardiotoxicity. In this study, anticancer activity of single drug as well as the drug combination effect of L-asparaginase (Celginase) and Trastuzumab (Herceptin) was studied on HER2 positive breast cancer (SKBR3) cells. Inhibition of cell proliferation assay based on fluorescence readout was studied to estimate the anticancer effect of the drugs. HUVEC cells were used as negative control cells. Individually as a single drug, Trastuzumab (Herceptin) and L-asparaginase (Celginase) showed anticancer activity against SKBR3 cells with IC50 value of 0.031ng/ml and 1.168µg/ml respectively. The drug combination interaction of Trastuzumab and L-asparaginase resulted in combination index of less than 1(CI < 1) showing their synergistic effect against SKBR3 cells. No cytotoxic effect was observed in control HUVEC cells. The results suggested that the antitumor activity of Trastuzumab and L-asparaginase against HER2 positive breast cancer was found specific to HER2 positive cancer (SKBR3) cells. This synergistic drug interaction of L-asparaginase and Trastuzumab could be further explored to as an alternative to current drug combination therapy against the HER2 positive breast cancer.


Cite this article:
Subhash Chand, Anu Sharma, Jai Prakash Prasad, Girish Sharma. Synergistic Combinatorial effect of L-asparaginase and Trastuzumab against HER2+ breast cancer cells. Research Journal of Pharmacy and Technology 2022; 15(12):5819-4. doi: 10.52711/0974-360X.2022.00982

Cite(Electronic):
Subhash Chand, Anu Sharma, Jai Prakash Prasad, Girish Sharma. Synergistic Combinatorial effect of L-asparaginase and Trastuzumab against HER2+ breast cancer cells. Research Journal of Pharmacy and Technology 2022; 15(12):5819-4. doi: 10.52711/0974-360X.2022.00982   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-12-76


REFERENCES:
1.    Hsu JL. Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35(4):575–588.doi: 10.1007/s10555-016-9649-6
2.    Wieduwilt MJ. Moasser MM. The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cell Mol Life Sci. 2008.65(10):1566–1584.doi: 10.1007/s00018-008-7440-8
3.    Walker F.  Kato A. Gonez LJ. Hibbs ML. Pouliot N. Levitzki A. Burgess AW. Activation of the Ras/Mitogen-Activated Protein Kinase Pathway by Kinase-Defective Epidermal Growth Factor Receptors Results in Cell Survival but Not Proliferation. Mol Cell Biol. 1998;18(12):7192–7204.doi:10.1128/mcb.18.12.7192
4.    Stanley A. Ashrafi GH. Seddon AM. Modjtahedi H. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Scientific Reports. 2017;7:3964.doi:10.1038/s41598-017-04301-8
5.    Sever R. Brugge JS. Signal Transduction in Cancer.Cold Spring HarbPerspect Med.2015;5(4):a006098.doi:10.1101/cshperspect.a006098
6.    Kirtishanti A. Siswandono S. Sudiana IK. Synthesis and Cytotoxic Activity of N-(4-bromo)-benzoyl-N’phenylthiourea and 4-(tert-butyl)-N-benzoylurea on Primary Cells of HER2-Positive Breast Cancer. Research J. Pharm. and Tech. 2021; 14(3):1195-1200.doi:10.5958/0974-360X.2021.00213.4
7.    Dange VN. Shid SJ. Magdum CS. Mohite SK. A Review on Breast cancer: An Overview. Asian J. Pharm. Res. 2017; 7(1): 49-51.doi:10.5958/2231-5691.2017.00008.9
8.    Tai W. Mahato R. Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264–275.doi:10.1016/j.jconrel.2010.04.009
9.    Maximiano S. Magalhaes P. Guerreiro MP. Morgado M. Trastuzumab in the Treatment of Breast Cancer. BioDrugs. 2016;30(2):75-86.doi:10.1007/s40259-016-0162-9
10.    Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics.  Oncogene. 2007;26(46): 6577–6592.doi:10.1038/sj.onc.1210478
11.    Lohman ES. Linn SC. Kok M. Low-dose doxorubicin combined with trastuzumab in HER2-positive metastatic breast cancer: A single institution experience. Journal of Clinical Oncology. 2014;32(15):e11598-e11598.doi:10.1200/jco.2014.32.15_suppl.e11598
12.    Yang F. Teves SS. Kemp CJ. Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochimicaet Biophysica Acta-Reviews on Cancer. 2014;1845(1):84-89.doi:10.1016/j.bbcan.2013.12.002
13.    Gorini S. DeAngelis A. Berrino L. Malara N. Rosano G. Ferraro E. Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.  Oxid Med Cell Longev. 2018:7582730.doi:10.1155/2018/7582730
14.    Ahmed AZ. Shetty P. Satyam SM. D’Souza MR. Herle AM. Singh VK. Methyl Gallate Mitigates Doxorubicin-Induced Peripheral Cytopenias: A Preclinical Experimental Study. Research J. Pharm. and Tech. 2021; 14(9):4529-4.doi:10.52711/0974-360X.2021.00788
15.    Shaty MH. Al-Ezzi MI. Arif IS. Basil S. Effect of Metformin on inflammatory markers involved in Cardiotoxicity induced by Doxorubicin. Research J. Pharm. and Tech. 2019; 12(12): 5815-5821.doi:10.5958/0974-360X.2019.01007.2
16.    Aruna P. Gayathiri NM. Cardioprotective Activity of Telmisartan, Metformin and its Combination against Doxorubicin Induced Myocardial Infarction in Rat Model. Research J. Pharm. and Tech. 2018; 11(12): 5293-5296.doi:10.5958/0974-360X.2018.00964.2
17.    Chandra AS. Shanmugapandiyan P. Cardioprotective efficacy of Tridax procumbens methanolic extract in Doxorubicin induced Oxidative Cardiac Damage. Research J. Pharm. and Tech. 2020; 13(1): 110-113.doi:10.5958/0974-360X.2020.00022.0
18.    Mandlem VKK. Priya NG. Raghavendra M. Abbulu K. Evaluation of Cardioprotective Activity of Tamarindus indica Linn Pericarpic extract in Doxorubicin induced Cardiotoxicity in Experimental Rats. Research J. Pharm. and Tech. 2020; 13(7): 3267-3273.doi:10.5958/0974-360X.2020.00579.X
19.    Chand S. Mahajan RV. Prasad JP. Sahoo DK. Mihooliya KN. Dhar MS. Sharma G. A comprehensive review on microbial L-asparaginase: Bioprocessing, characterization, and industrial applications. Biotechnol Appl Biochem. 2020;67(4):619-647.doi: 10.1002/bab.1888
20.    Subhashini A. Sangeetha VG. Pseudomonas montielli - A Potent Chemotherapeutic Asparaginase producing organism Isolated from Rhizosphere Soil. Research J. Pharm. and Tech 2020; 13(2):945-949.doi:10.5958/0974-360X.2020.00178.X
21.    Sundaramoorthi C. Dharamsi A. Evaluation of Bioparameters in the production of L-Asparaginase from Marine Thermophilic Fungal Isolate Penicillium notatum and its Immobilization Studies. Research J. Pharm. and Tech. 2019; 12(11):5505-5508.doi:10.5958/0974-360X.2019.00955.7
22.    Saravanan R. Dhachinamoorthi D. Renuga G. Senthilkumar K. Production of L-Asparaginase from Pectobacterium carotovorum (MTCC 1428) and Bacillus circulans (MTCC 1428). Research J. Pharm. and Tech. 2011;4(8):1323-1327.doi:Not Available.
23.    Chand S. Vaish U. Sharma A. Mishra NN. Prasad JP. Mahajan RV. A reliable assay for ensuring the biological activity of anti T lymphocyte immunoglobulin as an alternate to compendial flow cytometry method. Biologicals. 2020; 65:33-38.doi:10.1016/j.biologicals.2020.01.002
24.    Markovsky E. Baabur-Cohen H. Satchi-Fainaro R. Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. Journal of Controlled Release. 2014;187:145–157.https://doi.org/10.1016/j.jconrel.2014.05.025.
25.    Sharma G, Tyagi AK, Singh RP, Chan DCF, Agarwal R. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Breast Cancer Res Treat. 2004;85(1):1-12.doi:10.1023/B:BREA.0000020991.55659.59
26.    Shiromizu S, Kusunose N, Matsunaga N, Koyanagi S, Ohdo S. Optimizing the dosing schedule of L-asparaginase improves its antitumor activity in breast tumor-bearing mice. Journal of Pharmacological Sciences. 2018;36: 228-233.doi:10.1016/j.jphs.2018.01.008
27.    Knott SRV. Wagenblast E. Khan S. Kim SY. Soto M. Wagner M. Turgeon MO et al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 2018;554(7692): 378–381.doi:10.1038/nature25465

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available